Furthermore, patients achieving apCR had significantly superior disease-free survival (DFS) (HR = 0.29, 95% CI: 0.09-0.92, P = 0.036).<h4>Conclusions</h4>Our study developed and validated a preoperative nomogram that predicts apCR in HER2-positive BC by integrating three readily available clinical variables. The gene discussed is ERBB2; the disease is breast cancer.